Latest Insider Transactions at Bio Atla, Inc. (BCAB)
This section provides a real-time view of insider transactions for Bio Atla, Inc. (BCAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BioAtla, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BioAtla, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2021
|
Richard A Waldron Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,770
-1.79%
|
$144,250
$25.17 P/Share
|
|
Nov 22
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,675
-1.09%
|
$407,550
$26.23 P/Share
|
|
Nov 22
2021
|
Eric Sievers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
118
-0.13%
|
$3,068
$26.23 P/Share
|
|
Nov 22
2021
|
Scott Andrew Smith |
SELL
Open market or private sale
|
Direct |
430
-0.12%
|
$11,180
$26.23 P/Share
|
|
Nov 22
2021
|
Christian Vasquez Officer |
SELL
Open market or private sale
|
Direct |
691
-2.27%
|
$17,966
$26.23 P/Share
|
|
Nov 22
2021
|
Richard A Waldron Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,626
-2.18%
|
$94,276
$26.23 P/Share
|
|
Nov 02
2021
|
Lawrence Steinman |
SELL
Open market or private sale
|
Direct |
450
-2.38%
|
$13,500
$30.0 P/Share
|
|
Oct 01
2021
|
Eric Sievers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
592
-0.63%
|
$17,760
$30.39 P/Share
|
|
Oct 01
2021
|
Scott Andrew Smith |
SELL
Open market or private sale
|
Direct |
2,994
-0.84%
|
$89,820
$30.18 P/Share
|
|
Sep 30
2021
|
Guy Levy Director |
BUY
Grant, award, or other acquisition
|
Indirect |
267,900
+19.36%
|
$7,501,200
$28.0 P/Share
|
|
Sep 15
2021
|
Lawrence Steinman |
SELL
Open market or private sale
|
Direct |
450
-2.32%
|
$16,200
$36.82 P/Share
|
|
Aug 26
2021
|
Eric Sievers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,883
-6.84%
|
$268,437
$39.59 P/Share
|
|
Aug 26
2021
|
Scott Andrew Smith |
SELL
Open market or private sale
|
Direct |
33,244
-4.38%
|
$1,329,760
$40.26 P/Share
|
|
Aug 24
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
4,533
-0.57%
|
$185,853
$41.6 P/Share
|
|
Aug 24
2021
|
Jay M Phd Short Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
7,747
+0.96%
|
$139,446
$18.0 P/Share
|
|
Aug 24
2021
|
Guy Levy Director |
SELL
Open market or private sale
|
Indirect |
546,709
-19.67%
|
$21,321,651
$39.65 P/Share
|
|
Aug 16
2021
|
Lawrence Steinman |
SELL
Open market or private sale
|
Direct |
450
-2.27%
|
$18,000
$40.6 P/Share
|
|
Jul 15
2021
|
Lawrence Steinman |
SELL
Open market or private sale
|
Direct |
450
-2.22%
|
$17,100
$38.29 P/Share
|
|
Jul 07
2021
|
Jay M Phd Short Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
5,378
+0.41%
|
-
|
|
Jun 21
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
55,000
-2.2%
|
$2,145,000
$39.22 P/Share
|
|
Jun 17
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
19,269
-2.23%
|
$751,491
$39.22 P/Share
|
|
Jun 17
2021
|
Guy Levy Director |
SELL
Open market or private sale
|
Indirect |
400,000
-18.83%
|
$15,600,000
$39.16 P/Share
|
|
Jun 16
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
35,417
-1.98%
|
$1,381,263
$39.71 P/Share
|
|
Jun 15
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
32,023
-1.15%
|
$1,280,920
$40.21 P/Share
|
|
Jun 14
2021
|
Himalaya Parent LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
8,682,304
-100.0%
|
-
|
|
Jun 14
2021
|
Jay M Phd Short Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
78,697
-1.57%
|
$3,305,274
$42.42 P/Share
|
|
Jun 14
2021
|
Jay M Phd Short Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
1,692,056
+49.08%
|
-
|
|
Jun 14
2021
|
Jay M Phd Short Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
872,278
+37.7%
|
-
|
|
Jun 14
2021
|
Eric Sievers Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
23,726
+19.08%
|
-
|
|
Jun 14
2021
|
Scott Andrew Smith |
BUY
Other acquisition or disposition
|
Direct |
34,963
+8.27%
|
-
|
|
Jun 14
2021
|
Lawrence Steinman |
BUY
Other acquisition or disposition
|
Direct |
5,388
+21.01%
|
-
|
|
Jun 14
2021
|
Christian Vasquez Officer |
BUY
Other acquisition or disposition
|
Direct |
3,498
+10.31%
|
-
|
|
Jun 14
2021
|
Richard A Waldron Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
31,976
+16.1%
|
-
|
|
Dec 18
2020
|
Guy Levy Director |
BUY
Open market or private purchase
|
Indirect |
1,388,890
+50.0%
|
$25,000,020
$18.0 P/Share
|
|
Dec 18
2020
|
Guy Levy Director |
BUY
Conversion of derivative security
|
Indirect |
1,790,472
+50.0%
|
-
|
|
Dec 18
2020
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
800,000
+25.87%
|
$14,400,000
$18.0 P/Share
|
|
Dec 18
2020
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,492,060
+50.0%
|
-
|
|
Dec 18
2020
|
Pfizer Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,238,090
+50.0%
|
-
|